Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Septerna, Inc. - Common Stock (NQ:SEPN)

15.22 +0.55 (+3.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Septerna, Inc. - Common Stock

< Previous 1 2 Next >
Septerna to Participate in Upcoming Investor Conferences
From Septerna, Inc.
Via GlobeNewswire
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers 
From Septerna, Inc.
Via GlobeNewswire
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases. 
Via Benzinga
This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
The Analyst Verdict: Septerna In The Eyes Of 4 Experts
 
Via Benzinga
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
Septerna to Present at Jefferies Global Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well. 
Via MarketBeat
Topics World Trade
Where Septerna Stands With Analysts
 
Via Benzinga
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic amid mixed signals. 
Via Benzinga
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Which stocks have an unusual volume on Thursday?
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
Is It Time to Buy the Dip in Novo Nordisk Stock?
Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing 
Via MarketBeat
Topics Government
Top movers analysis in the middle of the day on 2025-05-14: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Dow Edges Higher; US Crude Oil Inventories Increase
 
Via Benzinga
Topics Stocks
Wednesday's pre-market session: top gainers and losers
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases. 
Via Benzinga
Nasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings
 
Via Benzinga
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing
The deal is worth up to $2.2 billion, including more than $200 million in upfront and near-term payments. 
Via Investor's Business Daily
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled
Septerna CEO Jeffrey Finer said that the collaboration allows the company to create multiple oral medicines and provides the operational flexibility and resources to advance its portfolio of other... 
Via Stocktwits
Topics Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
From Septerna, Inc.
Via GlobeNewswire
SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.